Wetherby Asset Management Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.4% during the second quarter, Holdings Channel reports. The firm owned 1,580 shares of the biopharmaceutical company’s stock after buying an additional 320 shares during the period. Wetherby Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $776,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Alpha Windward LLC boosted its stake in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares during the period. Concert Wealth Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 3 shares during the period. Cleararc Capital Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.3% in the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 5 shares during the period. Regentatlantic Capital LLC boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% in the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 5 shares during the period. Finally, Sheaff Brock Investment Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 10 shares during the period. Hedge funds and other institutional investors own 66.70% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 460.08 on Friday. The firm’s 50-day moving average price is $497.25 and its 200-day moving average price is $425.70. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The stock has a market cap of $48.78 billion, a P/E ratio of 46.16 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.84 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Wetherby Asset Management Inc. Has $776,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/wetherby-asset-management-inc-has-776000-stake-in-regeneron-pharmaceuticals-inc-nasdaqregn.html.

A number of brokerages recently weighed in on REGN. UBS AG set a $489.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a research note on Monday, May 15th. Piper Jaffray Companies upped their price objective on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 20th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Finally, Jefferies Group LLC restated a “hold” rating and set a $471.00 price objective (up from $418.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $489.35.

In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the transaction, the executive vice president now owns 43,950 shares in the company, valued at approximately $23,405,572.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the transaction, the chairman now owns 414,156 shares in the company, valued at approximately $189,741,429.84. The disclosure for this sale can be found here. Insiders have sold a total of 56,922 shares of company stock worth $27,383,105 in the last quarter. 10.40% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.